Respiratory syncytial virus natural treatment

In conclusion, recovery of RSV from the respiratory tract of cancer patients is common, occurs throughout the year, and is associated with a low rate of attributable respiratory complications. If confirmed by other prospective studies, our findings carry important implications for the management of cancer patients.

The publication costs of this article were defrayed in part by page charge payment. Sign In or Create an Account. Sign In. Skip Nav Destination Content Menu. Close Abstract. Patients, materials, and methods. Article Navigation. Anaissie , Elias J. This Site. Google Scholar. Tahsine H. Mahfouz , Tahsine H.

Turan Aslan , Turan Aslan. Anastasia Pouli , Anastasia Pouli. Rahman Desikan , Rahman Desikan. Athanasios Fassas , Athanasios Fassas. Bart Barlogie Bart Barlogie. Blood 5 : — Article history Submitted:. Cite Icon Cite. Figure 1. View large Download PPT. Figure 2. Table 1. Characteristics of myeloma patients according to RSV status.

View Large. Table 2. Before therapy Renal failure 17 59 22 Table 3. Before therapy Renal failure 20 56 26 Supported in part by grant no. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

J Infect Dis. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant. Respiratory virus infections after hematopoietic SCT.

Biol Blood Marrow Transplant. Community respiratory virus infections in bone marrow transplant recipients: The M. Anderson Cancer Center Experience. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins.

Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. Respiratory syncytial virus infections in immunocompromised adults.

Curr Clin Top Infect Dis. National surveillance for respiratory syncytial virus, United States, Molecular epidemiology of respiratory syncytial virus: a review of the use of reverse transcription-polymerase chain reaction in the analysis of genetic variability.

Epidemiological study on respiratory syncytial virus lower respiratory tract infections in northern Hokkaido, Japan [in Japanese]. Kansenshogaku Zasshi. Respiratory syncytial virus infections in human beings and in cattle. Currently, no palivizumab resistant RSV strains have been identified. Hospitalizations were reduced from The ICU length of stay, mechanical ventilation and incidence of otitis media were not altered with palivizumab. It is important to note that the incidence of mortality did not change with palivizumab.

Adverse reactions reported in the clinical trials included injection site reactions, rash, and increased liver function tests. There was no change in ICU admissions, mechanical ventilation or mortality.

Adverse effects included fever, injection site reactions and cyanosis 3. Because of these trials, palivizumab is FDA indicated in those children listed in Table 3 and this serves as the AAP recommended criteria for use. Cystic fibrosis patients may be administered palivizumab to prevent RSV infections; 63 , 64 however, no clinical trials are available at this time.

It is also important to consider the patient's insurance prior to administering the medication. Cost analyses have been conducted on both products.

In the other neonatal intensive care patients, the number needed to treat ranged from 15— Although palivizumab is the only product available today, if both were on the market, palivizumab typically would be favored based upon ease of administration, less adverse effects and lack of interference with live vaccines.

Currently no vaccine is available to prevent RSV. Previous versions, such as a formalin-inactivated vaccine, only led to more severe diseases in those exposed to natural disease. Potential future vaccines may consider other surface proteins for mechanisms of prevention.

Motavizumab Numax, MedImmune, Inc, Gaithersburg, Maryland is a second generation monoclonal antibody derived from palivizumab. It is more potent due to enhanced binding, fold increased binding to F protein than palivizumab. No difference was seen in mortality rates.

Mortality rates did not differ. The biological licensure application was submitted to the FDA in January of and the company is awaiting response. Motavizumab is also in phase 2 studies for treatment of RSV.

A third generation antibody is already in development, Numax-YTE, which has an extended serum half-life. Many questions remain regarding these newer agents and full release of data will assist with providing clinical efficacy information motavizumab vs. RSV is a disease that impacts millions of children each year. Supportive care including nutrition, hydration, clearing of nasal secretions, and oxygen, if needed, remains the mainstay therapy for patients.

Good handwashing techniques and contact isolation should be conducted to prevent RSV transmission. Those with risk factors, who meet inclusion criteria, should be administered palivizumab to prevent RSV infections. Ribavirin and palivizumab may be utilized for treatment in immunocompromised patients. Future vaccines could potentially decrease the economic burden of RSV in the healthcare setting.

National Center for Biotechnology Information , U. J Pediatr Pharmacol Ther. Lea S. Eiland , PharmD. Author information Copyright and License information Disclaimer.

Address correspondence to: Lea S. Eiland, Pharm. This article has been cited by other articles in PMC. Abstract Respiratory Syncytial Virus RSV is a common virus that infects children and adults; however, children younger than two years of age tend to develop more serious respiratory symptoms. Keywords: child, infant, palivizumab, ribavirin, motavizumab. Table 1. Open in a separate window. Table 2. Bronchodilators Treatment of RSV with inhaled bronchodilators such as albuterol and epinephrine is debatable.

Corticosteroids Corticosteroids of all forms oral, inhaled, intravenous, intramuscular are not recommended for routine use in children for RSV. Antibiotics Antibiotics are not recommended as RSV is a viral infection. Palivizumab In , palivizumab was approved for use of preventing RSV infections in specific patient populations Table 3. Table 3. Respiratory Syncytial Virus.

Principles and Practice of Pediatric Infectious Diseases. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.

Leader S, Kohlhase K. J Pediatr. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, — J Infect Dis.

Epub Nov Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Respiratory syncytial virus infection in elderly and high-risk adults.

N Engl J Med. Murata Y, Falsey AR. Respiratory syncytial virus infection in adults. Section Navigation. Facebook Twitter LinkedIn Syndicate. Minus Related Pages. Know the symptoms to look for and how to care for people with RSV. Conclusion: We suggest the development of local and regional guidelines based on hospitalisation rates in high-risk infants and cost-benefit analysis studies. Abstract This review discusses the current knowledge on treatment and prevention of respiratory syncytial virus RSV infections in children.

Publication types Review.